Home » Drug Information » FDA-Approved Drugs » 1995
Medical Areas: Endocrinology | Obstetrics/Gynecology | Oncology
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Alza
Approval Status: Approved December 8, 1995
Treatment Area: ovarian cancer
Ethyol has been approved to reduce the renal toxicity associated
with repeated administration of chemotherapy in subjects with
advanced ovarian cancer. Currently, there are only limited data on
the effects of Ethyol on the efficacy of chemotherapy in other
settings. Ethyol should not be administered to patients receiving
chemotherapy for malignancies that are commonly curable, except in
the context of a clinical study.
Pretreatment with Ethyol significantly reduced the cumulative
renal toxicity associated with multiple cycles of chemotherapy.
The most common adverse effects of Ethyol were vomiting, low
blood pressure, somnolence, and sneezing. Vomiting, hypotension,
and somnolence were more common with higher drug doses. In a phase
I trial, vomiting and somnolence were experienced significantly
more frequently by women than men.
Spencer, C. and Goa, Karen. Amifostine: A Review of its
Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic
Potential as a Radioprotector and Cytoxic Chemoprotector.
Drugs 50(6): 1001-1031, 1995.
